LegoChem Biosciences (LCB) has entered an exclusive worldwide licensing agreement with Glycotope to develop an antibody-drug conjugate (ADC).
Building on the collaboration and licence deal the two companies signed in 2022, this latest agreement will bring together LCB鈥檚 ADC technology and one of Glycotope鈥檚 investigational antibodies.
Financial terms of the transaction have not been disclosed.
LCB will gain global exclusive rights to develop and commercialise the selected antibody as an ADC.
LCB will make an upfront payment to Glycotope, which is then entitled to receive clinical, regulatory, sales and milestone payments, and royalties on net sales worldwide.
The antibodies developed by Glycotope target particular tumour-linked carbohydrate structures or protein/carbohydrate combined glyco-epitopes (GlycoTargets).
US Tariffs are shifting - will you react or anticipate?
Don鈥檛 let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataGlycotope chief scientific officer Patrik Kehler stated: 鈥淲e believe this antibody has excellent potential for the treatment of several solid tumour indications with high medical need.
鈥淭he continued progress of our collaboration with LCB, a leading developer of next-generation therapeutics, further highlights the importance of tumour-associated glycosylation in the treatment of cancer and underlines the strengths of our technology.鈥�
Compared to existing technologies, LCB鈥檚 ADC platform technologies showcase site-specific stable bioconjugation, cancer-selective linker activation and cancer-selective activation of potent payload.
LegoChem Biosciences CEO and president Dr Yong-Zu Kim stated: 鈥淲ith the licensing of the antibody for the development as an ADC, we are further expanding the number of ADCs we have under development, which demonstrates our commitment to maximising the value of our ADC payload and linker technology.
鈥淲e look forward to advancing the programme to clinical stage.鈥�
